
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/387906/publications.pdf Version: 2024-02-01



Ρετέρ Ρ Τότμ

#	Article	IF	CITATIONS
1	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
2	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	1.5	5
3	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	1.0	1
4	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)â€Free Lowâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2022, 11, e023136.	1.6	8
5	Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement✰. American Journal of Preventive Cardiology, 2022, 9, 100318.	1.3	16
6	CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC: Cardiovascular Imaging, 2022, 15, 641-651.	2.3	11
7	Substantially elevated TSH, not traditional clinical subclinical thyroid disorder groupings, are associated with smaller LDL-P mean size: ELSA-Brasil. Journal of Clinical Lipidology, 2022, , .	0.6	0
8	Contemporary Management of Dyslipidemia. Drugs, 2022, 82, 559-576.	4.9	14
9	President's page: ASPC is leading the way in preventive cardiology. American Journal of Preventive Cardiology, 2022, 9, 100321.	1.3	0
10	Stepâ€byâ€step diagnosis and management of the nocebo/drucebo effect in statinâ€associated muscle symptoms patients: a position paper from <i>the International Lipid Expert Panel</i> (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	2.9	35
11	Ten things to know about ten cardiovascular disease risk factors – 2022. American Journal of Preventive Cardiology, 2022, 10, 100342.	1.3	34
12	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 10, 100335.	1.3	58
13	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATV000000000000153.	1.1	167
14	ASPC President's Page: Getting back To Basics One Patient at a Time. American Journal of Preventive Cardiology, 2022, , 100350.	1.3	0
15	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. American Heart Journal Plus, 2022, 17, 100148.	0.3	4
16	The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel. International Journal of Molecular Sciences, 2022, 23, 7326.	1.8	30
17	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 346-351.	1.4	3
18	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. Postgraduate Medicine, 2021, 133, 125-139.	0.9	8

#	Article	IF	CITATIONS
19	Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system. Postgraduate Medicine, 2021, 133, 140-145.	0.9	8
20	Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. Endocrinology, 2021, 162, .	1.4	4
21	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiology, 2021, 17, 155-174.	0.5	14
22	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. Trends in Cardiovascular Medicine, 2021, 31, 49-56.	2.3	12
23	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. Contemporary Cardiology, 2021, , 1-22.	0.0	0
24	ASPC President's Page: Addressing Unmet Needs in Preventive Cardiology. American Journal of Preventive Cardiology, 2021, 5, 100155.	1.3	0
25	Branched-chain amino acids predict incident diabetes in the Brazilian Longitudinal Study of Adult Health – ELSA-Brasil. Diabetes Research and Clinical Practice, 2021, 174, 108747.	1.1	8
26	INCREASED INPATIENT MORTALITY FOR CARDIOVASCULAR PATIENTS DURING THE FIRST WAVE OF THE COVID-19 EPIDEMIC IN NEW YORK. Journal of the American College of Cardiology, 2021, 77, 3042.	1.2	0
27	ASPC President's Page: Advancing and Refining Cardiovascular Disease Prevention. American Journal of Preventive Cardiology, 2021, 6, 100194.	1.3	0
28	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovascular Diabetology, 2021, 20, 125.	2.7	11
29	Ten things to know about ten imaging studies: A preventive cardiology perspective ("ASPC top ten) Tj ETQq	1 1 0 7843 1.3	314 ₉ rgBT /Ove
30	Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines American Journal of Preventive Cardiology, 2021, 6, 100186.	1.3	4
31	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Medicine, 2021, 19, 139.	2.3	22
32	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	1.6	39
33	Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database. Future Cardiology, 2021, 17, 743-755.	0.5	8
34	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Archivos De Cardiologia De	0.1	4
35	Mexico, 2021, 92, . Statin Prescribing and Dosing—Failure Has Become an Option. JAMA Cardiology, 2021, 6, 854.	3.0	1
36	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021, 83, 1703-1715.	1.2	15

#	Article	IF	CITATIONS
37	Celebrating ASPC's achievements and introducing new educational offerings. American Journal of Preventive Cardiology, 2021, 7, 100226.	1.3	0
38	That Myalgia of Yours Is Not From StatinÂIntolerance. Journal of the American College of Cardiology, 2021, 78, 1223-1226.	1.2	6
39	Hepatic Sensing Loop Regulates PCSK9ÂSecretion in Response to Inhibitory Antibodies. Journal of the American College of Cardiology, 2021, 78, 1437-1449.	1.2	13
40	Statins: Then and Now. Methodist DeBakey Cardiovascular Journal, 2021, 15, 23.	0.5	54
41	Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. Contemporary Cardiology, 2021, , 269-294.	0.0	0
42	Atherogenesis and Vascular Biology. Contemporary Cardiology, 2021, , 11-34.	0.0	1
43	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. Journal of Clinical Medicine, 2021, 10, 5656.	1.0	9
44	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Frontiers in Cardiovascular Medicine, 2021, 8, 787761.	1.1	38
45	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition, 2020, 39, 1742-1752.	2.3	106
46	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. American Journal of Cardiovascular Drugs, 2020, 20, 1-9.	1.0	9
47	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology, 2020, 27, 1597-1605.	0.8	41
48	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	2.2	33
49	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. Metabolites, 2020, 10, 392.	1.3	34
50	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. Atherosclerosis, 2020, 312, 60-65.	0.4	4
51	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. American Journal of Preventive Cardiology, 2020, 3, 100086.	1.3	10
52	Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 2020, 4, 100130.	1.3	142
53	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study). Lipids in Health and Disease, 2020, 19, 237.	1.2	8
54	Cardiovascular Risk and Statin Therapy Considerations in Women. Diagnostics, 2020, 10, 483.	1.3	45

#	Article	IF	CITATIONS
55	Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. American Journal of Preventive Cardiology, 2020, 2, 100040.	1.3	1
56	Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. Metabolites, 2020, 10, 428.	1.3	17
57	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Archives of Medical Science, 2020, 16, 1279-1287.	0.4	11
58	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National) Tj ETQqO 0 () rgBT /Ov 0.7	erlock 10 Tf
59	Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014. American Journal of Preventive Cardiology, 2020, 3, 100087.	1.3	3
60	Prevalence of US Adults with Triglycerides ≥ 150Âmg/dl: NHANES 2007–2014. Cardiology and The 2020, 9, 207-213.	erapy, 1.1	35
61	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology, 2020, 1, 100009.	1.3	90
62	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Current Atherosclerosis Reports, 2020, 22, 18.	2.0	26
63	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1565.	3.8	103
64	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). Nutrition Research Reviews, 2020, 33, 155-179.	2.1	31
65	Effect of Evolocumab on Nonâ€Highâ€Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. Journal of the American Heart Association, 2020, 9, e014129.	1.6	25
66	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	3.1	17
67	Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .	2.2	0
68	Recommendations of statin treatment after acute coronary syndrome: Hungarian experiences. Atherosclerosis, 2020, 303, 53-54.	0.4	1
69	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. Clinical Nutrition, 2020, 39, 3677-3686.	2.3	52
70	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atherosclerosis Supplements, 2020, 42, e15-e24.	1.2	18
71	Familial Hypercholesterolemia andÂLipoprotein(a). Journal of the American College of Cardiology, 2020, 75, 2694-2697.	1.2	2
72	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	0.7	38

#	Article	IF	CITATIONS
73	Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). Experimental and Therapeutic Medicine, 2020, 21, 90.	0.8	6
74	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2020, 18, 604-616.	0.4	9
75	The bandwidth of preventive cardiology continues to increase: Meeting the challenge head on. American Journal of Preventive Cardiology, 2020, 4, 100132.	1.3	0
76	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular Research, 2019, 115, 204-212.	1.8	34
77	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of Clinical Lipidology, 2019, 13, 754-761.	0.6	10
78	Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in highâ€risk statinâ€treated patients: A large administrative retrospective analysis. Clinical Cardiology, 2019, 42, 908-913.	0.7	10
79	INCREASED RESIDUAL CARDIOVASCULAR RISK IN US VETERANS AND MONERATELY-ELEVATED BASELINE TRIGLYCERIDES AND WELL-CONTROLLED LDL-C LEVELS ON STATINS. Journal of the American College of Cardiology, 2019, 73, 1719.	1.2	2
80	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. Journal of Clinical Lipidology, 2019, 13, 634-644.	0.6	32
81	Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids in Health and Disease, 2019, 18, 175.	1.2	48
82	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. Archives of Medical Research, 2019, 50, 362-367.	1.5	14
83	Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. Journal of Clinical Lipidology, 2019, 13, 997-1007.e8.	0.6	6
84	Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). American Journal of Cardiology, 2019, 124, 1165-1170.	0.7	5
85	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. Mayo Clinic Proceedings, 2019, 94, 1670-1680.	1.4	45
86	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. Journal of Clinical Lipidology, 2019, 13, 804-811.e2.	0.6	10
87	Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients. CardioRenal Medicine, 2019, 9, 400-407.	0.7	14
88	Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients. Experimental Biology and Medicine, 2019, 244, 1089-1095.	1.1	8
89	Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil). Maturitas, 2019, 130, 32-37.	1.0	12
90	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. Diabetes Care, 2019, 42, 2307-2314.	4.3	43

#	Article	IF	CITATIONS
91	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. American Heart Journal, 2019, 217, 72-83.	1.2	45
92	Trends in Lipids, Obesity, Metabolic Syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003â€2004 to 2013â€2014). Obesity, 2019, 27, 309-314.	1.5	94
93	Response to "Trends in Obesity, NHANES 2003â€2004 to 2013â€2014: Is Waist Circumference Increasing Independently of Body Mass Index?― Obesity, 2019, 27, 1044.	1.5	0
94	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2019, 143, 1-16.	3.1	90
95	Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients, 2019, 11, 2580.	1.7	39
96	Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients. Vascular Health and Risk Management, 2019, Volume 15, 533-538.	1.0	13
97	Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. Journal of Clinical Lipidology, 2019, 13, 100-108.	0.6	56
98	Composite acute phase glycoproteins with coronary artery calcification depends on metabolic syndrome presence – The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Journal of Cardiology, 2019, 73, 408-415.	0.8	8
99	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. Clinical Biochemistry, 2019, 64, 24-29.	0.8	36
100	Management of Dyslipidemia. Contemporary Cardiology, 2019, , 39-69.	0.0	0
101	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. Current Vascular Pharmacology, 2019, 17, 376-378.	0.8	2
102	Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014. Cardiology Journal, 2019, 26, 604-606.	0.5	6
103	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International, 2018, 93, 1397-1408.	2.6	83
104	Management of Statin Intolerance in 2018: Still More Questions Than Answers. American Journal of Cardiovascular Drugs, 2018, 18, 157-173.	1.0	130
105	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGHÂtrial. Journal of Clinical Lipidology, 2018, 12, 741-747.e11.	0.6	6
106	Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. Current Atherosclerosis Reports, 2018, 20, 20.	2.0	62
107	Effect of Evolocumab on Lipoprotein Particles. American Journal of Cardiology, 2018, 121, 308-314.	0.7	29
108	Introducing the â€~Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statinâ€associated muscle symptoms, under blinded and openâ€label conditions. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 1023-1033.	2.9	84

#	Article	IF	CITATIONS
109	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Realâ€World Administrative Claims Analysis of Statinâ€Treated Patients With High Residual Cardiovascular Risk. Journal of the American Heart Association, 2018, 7, e008740.	1.6	81
110	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. European Journal of Preventive Cardiology, 2018, 25, 1966-1976.	0.8	50
111	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. Journal of Clinical Lipidology, 2018, 12, 1290-1297.e1.	0.6	10
112	Natural approaches in metabolic syndrome management. Archives of Medical Science, 2018, 14, 422-441.	0.4	103
113	Novel Therapeutic Targets for Managing Dyslipidemia. Trends in Pharmacological Sciences, 2018, 39, 733-747.	4.0	31
114	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. Current Pharmaceutical Design, 2018, 24, 239-258.	0.9	87
115	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. Journal of Medical Economics, 2017, 20, 555-564.	1.0	49
116	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. Current Medical Research and Opinion, 2017, 33, 869-876.	0.9	5
117	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation, 2017, 135, 1819-1831.	1.6	67
118	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2017, 11, 972-985.e9.	0.6	40
119	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2017, 122, 105-117.	3.1	21
120	<scp>PCSK9</scp> inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers. Clinical Cardiology, 2017, 40, 243-254.	0.7	71
121	Systematic Review and Network Metaâ€Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. Journal of the American Heart Association, 2017, 6, .	1.6	61
122	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	2.6	238
123	Association Between Smoking and Serum GlycA and Highâ€Sensitivity Câ€Reactive Protein Levels: The Multiâ€Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSAâ€Brasil). Journal of the American Heart Association, 2017, 6, .	1.6	27
124	Baseline Characteristics of a Retrospective Claims Analysis of Cardiovascular Outcomes and Health Care Resource Utilization and Costs in High-Risk Statin-Treated Patients With Hypertriglyceridemia. Journal of Clinical Lipidology, 2017, 11, 797.	0.6	1
125	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2017, 31, 419-431.	1.3	45
126	Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. Journal of Clinical Lipidology, 2017, 11, 1152-1160.e2.	0.6	83

#	Article	IF	CITATIONS
127	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. American Journal of Cardiology, 2017, 120, 1521-1527.	0.7	36
128	What is sufficient drug therapy for lipoprotein elevations?. Journal of Clinical Lipidology, 2017, 11, 1300-1308.	0.6	0
129	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. BMC Medicine, 2017, 15, 83.	2.3	38
130	All-Cause and Acute Pancreatitis Health Care Costs in Patients With Severe Hypertriglyceridemia. Pancreas, 2017, 46, 57-63.	0.5	8
131	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.4	206
132	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. Current Pharmaceutical Design, 2017, 23, 2496-2503.	0.9	31
133	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vascular Health and Risk Management, 2016, 12, 185.	1.0	16
134	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vascular Health and Risk Management, 2016, 12, 171.	1.0	166
135	Molecular mechanisms of statin intolerance. Archives of Medical Science, 2016, 3, 645-658.	0.4	58
136	Systematic Review of Lowâ€Đensity Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. Journal of the American Heart Association, 2016, 5, .	1.6	77
137	IMPROVE-IT. Current Opinion in Cardiology, 2016, 31, 426-433.	0.8	16
138	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2016, 107, 360-371.	3.1	61
139	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. Journal of Diabetes and Its Complications, 2016, 30, 1365-1370.	1.2	10
140	Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. Journal of Clinical Lipidology, 2016, 10, 880-890.	0.6	47
141	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids in Health and Disease, 2016, 15, 22.	1.2	25
142	Statin combination therapy and cardiovascular risk reduction. Future Cardiology, 2016, 12, 289-315.	0.5	13
143	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 2016, 5, .	1.6	121
144	Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?. International Journal of Cardiology, 2016, 215, 47-59.	0.8	24

#	Article	IF	CITATIONS
145	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 206-212.	0.9	71
146	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. American Journal of Cardiology, 2016, 118, 19A-32A.	0.7	8
147	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. American Journal of Cardiology, 2016, 118, 1812-1820.	0.7	7
148	The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. Journal of Clinical Lipidology, 2016, 10, 1452-1461.	0.6	13
149	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology, 2016, 225, 184-196.	0.8	155
150	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016, 253, 194-208.	0.4	142
151	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. Journal of Clinical Lipidology, 2016, 10, 1248-1258.	0.6	29
152	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSAâ€Brasil). Clinical Cardiology, 2016, 39, 215-222.	0.7	5
153	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. Atherosclerosis, 2016, 252, 1-8.	0.4	26
154	Productivity losses associated with cardiovascular disease: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 759-769.	0.7	38
155	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 30060.	1.6	25
156	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Annals of Internal Medicine, 2016, 165, 867.	2.0	84
157	PCSK9 and Lipoprotein(a). Circulation Research, 2016, 119, 3-6.	2.0	5
158	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids in Health and Disease, 2016, 15, 28.	1.2	36
159	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacological Research, 2016, 111, 343-356.	3.1	19
160	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. Clinical Therapeutics, 2016, 38, 603-609.	1,1	12
161	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacological Research, 2016, 103, 236-252.	3.1	60
162	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. European Journal of Preventive Cardiology, 2016, 23, 41-49.	0.8	64

#	Article	IF	CITATIONS
163	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Medicine, 2015, 13, 229.	2.3	169
164	Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. Clinical Cardiology, 2015, 38, 483-491.	0.7	33
165	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science, 2015, 1, 1-23.	0.4	311
166	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis, 2015, 241, 433-442.	0.4	139
167	The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids in Health and Disease, 2015, 14, 29.	1.2	44
168	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. European Journal of Preventive Cardiology, 2015, 22, 849-854.	0.8	60
169	Is HPS2-THRIVE the death knell for niacin?. Journal of Clinical Lipidology, 2015, 9, 343-350.	0.6	9
170	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	0.6	5
171	Is the Guideline Process Replicable and, if Not, What Does This Mean?. Progress in Cardiovascular Diseases, 2015, 58, 3-9.	1.6	2
172	Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research, 2015, 99, 329-336.	3.1	145
173	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol. Circulation, 2015, 132, 667-676.	1.6	41
174	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis, 2015, 242, 87-96.	0.4	47
175	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis, 2015, 242, 243-250.	0.4	93
176	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. Journal of Clinical Lipidology, 2015, 9, 576-582.	0.6	56
177	Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. American Journal of Cardiology, 2015, 115, 1204-1211.	0.7	19
178	Recommendations for the Management of Patients with Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2015, 17, 473.	2.0	13
179	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety, 2015, 14, 935-955.	1.0	117
180	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1873-1875.	1.2	4

#	Article	IF	CITATIONS
181	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1
182	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). Journal of Clinical Lipidology, 2015, 9, 676-683.	0.6	14
183	Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients. International Journal of Cardiology, 2015, 178, 111-116.	0.8	154
184	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	1.0	142
185	Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Frontiers in Pharmacology, 2015, 6, 299.	1.6	92
186	Hot Topics in Primary Care: Familial Hypercholesterolemia in Youth. Journal of Family Practice, 2015, 64, S22-30.	0.2	0
187	Dysfunctional HDL: the journey from savior to slayer. Clinical Lipidology, 2014, 9, 49-59.	0.4	15
188	Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Midâ€Life: The Very Large Database of Lipids (VLDLâ€10B). Journal of the American Heart Association, 2014, 3, e000851.	1.6	54
189	Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. Annals of Medicine, 2014, 46, 341-352.	1.5	1
190	An Update on the Benefits and Risks of Rosuvastatin Therapy. Postgraduate Medicine, 2014, 126, 7-17.	0.9	14
191	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 453-461.	2.2	64
192	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	0.6	98
193	Prevalence of dyslipidemia and associated risk factors in Turkish adults. Journal of Clinical Lipidology, 2014, 8, 206-216.	0.6	99
194	Residual macrovascular risk in 2013: what have we learned?. Cardiovascular Diabetology, 2014, 13, 26.	2.7	149
195	HDL Hypothesis: Where Do We Stand Now?. Current Atherosclerosis Reports, 2014, 16, 398.	2.0	24
196	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 353-368.	2.2	61
197	Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. Atherosclerosis, 2014, 237, 790-797.	0.4	16
198	Taking a longer term view of cardiovascular risk: the causal exposure paradigm. BMJ, The, 2014, 348, g3047-g3047.	3.0	23

#	Article	IF	CITATIONS
199	The Therapeutic Role of Niacin in Dyslipidemia Management. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 141-158.	1.0	52
200	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. Journal of Clinical Lipidology, 2014, 8, 594-605.	0.6	11
201	JCL Roundtable: HDL in the primary care setting. Journal of Clinical Lipidology, 2014, 8, 364-372.	0.6	4
202	Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis, 2014, 237, 319-335.	0.4	39
203	High-density lipoprotein subfractions: current views and clinical practice applications. Trends in Endocrinology and Metabolism, 2014, 25, 329-336.	3.1	42
204	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Journal of Clinical Lipidology, 2014, 8, 107-116.	0.6	31
205	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	0.8	316
206	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis, 2014, 235, 585-591.	0.4	53
207	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
208	Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease. Current Vascular Pharmacology, 2014, 12, 653-657.	0.8	43
209	Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice. Reviews in Cardiovascular Medicine, 2014, 15, 1-10.	0.5	24
210	High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 484-525.	0.6	276
211	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA - Journal of the American Medical Association, 2013, 310, 2061.	3.8	568
212	Non–High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. Journal of the American College of Cardiology, 2013, 62, 1960-1965.	1.2	59
213	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology, 2013, 62, 732-739.	1.2	331
214	Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management ofÂhypercholesterolemia. Journal of Clinical Lipidology, 2013, 7, S6-S10.	0.6	32
215	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research, 2013, 72, 35-44.	3.1	90
216	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2013, 29, 435-451.	0.9	36

#	Article	IF	CITATIONS
217	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clinical Lipidology, 2013, 8, 13-41.	0.4	23
218	Stroke Prevention in Patients With Atrial Fibrillation: Focus on New Oral Anticoagulants. Postgraduate Medicine, 2013, 125, 155-161.	0.9	1
219	Very Large Database of Lipids: Rationale and Design. Clinical Cardiology, 2013, 36, 641-648.	0.7	39
220	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vascular Health and Risk Management, 2013, 9, 719.	1.0	28
221	Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction. Current Diabetes Reviews, 2012, 8, 219-228.	0.6	4
222	Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006. Journal of Clinical Lipidology, 2012, 6, 325-330.	0.6	206
223	Glucolipotoxicity and the Heart. Heart Failure Clinics, 2012, 8, xvii-xviii.	1.0	4
224	Epicardial Steatosis, Insulin Resistance, and Coronary Artery Disease. Heart Failure Clinics, 2012, 8, 671-678.	1.0	16
225	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effectsAon low-density lipoprotein-cholesterol reduction. Journal of Clinical Lipidology, 2012, 6, 180-191.	0.6	19
226	The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2012, 11, 109.	2.7	75
227	Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management, 2012, 8, 415.	1.0	169
228	Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vascular Health and Risk Management, 2012, 8, 39.	1.0	24
229	Addressing key questions with statin therapy. Journal of Family Practice, 2012, 61, S34-9.	0.2	0
230	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, 133-140.	0.6	483
231	Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology, 2011, 5, S9-S17.	0.6	292
232	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, S1-S8.	0.6	406
233	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	0.6	235
234	Antisense therapy and emerging applications for the management of dyslipidemia. Journal of Clinical Lipidology, 2011, 5, 441-449.	0.6	24

#	Article	IF	CITATIONS
235	Drug safety evaluation of rosuvastatin. Expert Opinion on Drug Safety, 2011, 10, 969-986.	1.0	27
236	Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. Journal of Clinical Hypertension, 2011, 13, 42-51.	1.0	7
237	Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology, 2010, 5, 655-684.	0.4	33
238	Activation of intracellular signaling systems by high-density lipoproteins. Journal of Clinical Lipidology, 2010, 4, 376-381.	0.6	16
239	Drug Treatment of Hyperlipidaemia. Drugs, 2010, 70, 1363-1379.	4.9	42
240	Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vascular Health and Risk Management, 2010, 6, 1065.	1.0	10
241	The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes. Postgraduate Medicine, 2009, 121, 59-72.	0.9	5
242	Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids. Current Atherosclerosis Reports, 2009, 11, 71-79.	2.0	32
243	An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Atherosclerosis: the underlying disease. Journal of Family Practice, 2009, 58, S19-25.	0.2	6
244	An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Commentary. Journal of Family Practice, 2009, 58, S41-3.	0.2	2
245	An Urgent Matter. Identifying Your Patients' Cardiovascular Risk and Improving Their Outcomes. Introduction. Journal of Family Practice, 2009, 58, S17-8.	0.2	1
246	When high is low: Raising low levels of high-density lipoprotein cholesterol. Current Cardiology Reports, 2008, 10, 488-496.	1.3	13
247	A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia) Tj ETQo therapy for dyslipidemia?. Journal of Clinical Lipidology, 2008, 2, 313-317.	1 1 0.78 1 1 0.6	4314 rgBT / 19
248	High-dose statin therapy: benefits and safety in aggressive lipid lowering. Journal of Family Practice, 2008, 57, S29-36.	0.2	4
249	Torcetrapib and atherosclerosis: what happened and where do we go from here?. Future Lipidology, 2007, 2, 277-284.	0.5	12
250	Making a Case for Quantitative Assessment of Cardiovascular Risk. Journal of Clinical Lipidology, 2007, 1, 234-241.	0.6	19
251	Adiponectin and high-density lipoprotein: a metabolic association through thick and thinThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2005, 26, 1579-1581.	1.0	20
252	The "Good Cholesterol― Circulation, 2005, 111, e89-91.	1.6	75

#	Article	IF	CITATIONS
253	High-Density Lipoprotein and Cardiovascular Risk. Circulation, 2004, 109, 1809-1812.	1.6	113
254	Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clinical Therapeutics, 2004, 26, 1355-1367.	1.1	109
255	C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. Current Atherosclerosis Reports, 2003, 5, 341-349.	2.0	93
256	Reverse cholesterol transport: High-density lipoprotein's magnificent mile. Current Atherosclerosis Reports, 2003, 5, 386-393.	2.0	69
257	High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects. Disease-a-Month, 2001, 47, 365-416.	0.4	23